Morgan Stanley’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-207,755
Closed -$23.1K 7933
2022
Q4
$23.1K Sell
207,755
-4,399
-2% -$2.81K ﹤0.01% 6627
2022
Q3
$225K Buy
212,154
+197,022
+1,302% +$449K ﹤0.01% 5680
2022
Q2
$28K Buy
15,132
+1,771
+13% +$4.3K ﹤0.01% 6862
2022
Q1
$48K Buy
13,361
+803
+6% +$3.94K ﹤0.01% 6729
2021
Q4
$109K Sell
12,558
-1,415
-10% -$9K ﹤0.01% 6391
2021
Q3
$105K Buy
13,973
+1,925
+16% +$16.2K ﹤0.01% 6345
2021
Q2
$80K Buy
12,048
+6,901
+134% +$43.5K ﹤0.01% 6451
2021
Q1
$62K Buy
+5,147
New +$102K ﹤0.01% 6257

Other funds holding LHDX

Morgan Stanley's LHDX Position: Q1 2023 in Review

Morgan Stanley sold out of Lucira Health, Inc. Common Stock (LHDX) in Q1 2023, closing a stake of 207,755 shares — an estimated $23.1K sold.

Morgan Stanley first reported a position in LHDX in Q1 2021 and held it in 8 quarters. The position peaked at $225K in Q3 2022. 6 funds tracked by Wall St. Rank hold LHDX as of Q1 2023.

  • Morgan Stanley reported no remaining Lucira Health, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Morgan Stanley sold 207,755 Lucira Health, Inc. Common Stock shares in Q1 2023, an estimated $23.1K.
  • Morgan Stanley first reported a position in Lucira Health, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
  • Morgan Stanley's Lucira Health, Inc. Common Stock position peaked at $225K in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Lucira Health, Inc. Common Stock as of Q1 2023.

Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.